Clinical current and anti-viral therapy of adenoviral keratoconjunctivitis
Abstract
AbstractThis study presents the clinical efficacy of the antiviral drug "Virostav" in patients with adenoviral keratoconjunctivitis. On the background of therapy with Virostav, complete recovery with restoration of normal vision was revealed in 69.2% of patients, and partial recovery with subsequent complete restoration of vision in 30.8% of patients. The effectiveness of the drug with complete recovery of patients with adenoviral conjunctivitis was 76.9%. The convenient and ready-to-use drug Virostav has a pronounced therapeutic effect in the complex treatment of patients with both adenoviral keratoconjunctivitis and adenoviral conjunctivitis, this is the basis that the drug Virostav is promising in the treatment of patients with viral eye lesions.